The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
May 1st 2025
Patients with neovascular age-related macular degeneration (nAMD) experienced improvements in central macular thickness and subretinal and intraretinal fluid after switching.
Cost Burden of Hospital-Onset CDI Higher Than Community-Associated CDI
August 11th 2023Researchers found that costs were highest for those with hospital-onset clostridioides difficile infection (CDI), lower for those with community onset-health care facility association CDI, and lowest for those with community-associated CDI.
Read More
Active AD Prevalent in 2.4% of the UK Adult Population
August 10th 2023Researchers found that 2.4% of the adult UK population had active atopic dermatitis (AD) between 2015 and 2019, the majority of which were mild cases of AD, as only 7.5% to 8.3% of the population had moderate to severe AD.
Read More
Atorvastatin May Mitigate Risk of Cardiac Events Due to Anthracycline Use in Lymphoma
August 10th 2023Anthracyclines are widely used to treat hematological and solid-tumor cancers, but past research suggests their use may be associated with late cardiac effects, including heart failure, among patients with lymphomas and other cancers.
Read More
Small Study Shows Utility of ctDNA for Monitoring Treatment Response, Evolution of MDS, AML
August 9th 2023Investigators from China used circulating tumor DNA testing alongside bone marrow assessments to evaluate patients' pretreatment and posttreatment disease levels and to track the course of the disease.
Read More
Dr Kami Maddocks: Advances in DLBCL Treatment Despite Challenges in Research
August 8th 2023Although B-cell lymphomas can be challenging to study, there have been great advances in treatments in the second-line and later, explained Kami Maddocks, MD, professor of Clinical Internal Medicine, the Ohio State James Comprehensive Cancer Center.
Read More
Gilead Discontinues Phase 3 ENHANCE Trial of Magrolimab/Azacitidine in Higher-Risk MDS
August 7th 2023The phase 3 ENHANCE trial evaluating the first-line combination of magrolimab and azacitidine vs placebo plus azacitidine in patients with higher-risk myelodysplastic syndrome has been discontinued due to futility at a planned analysis.
Read More
Zilucoplan Demonstrates Consistent Efficacy in Phase 3 RAISE Study of Generalized Myasthenia Gravis
August 5th 2023Nearly half of patients treated with zilucoplan were considered responders on Myasthenia Gravis Activities of Daily Living (MG-ADL) at the first week, suggesting a rapid onset of efficacy.
Read More
What We’re Reading: Historic Low of Uninsured; Youth Gender Treatments; Birth Control Recall
August 4th 2023A record low of 7.7% of Americans had no health insurance at the start of 2023; the American Academy of Pediatrics renewed its backing of gender care for children while requesting a research review; 2 lots of an oral contraceptive were recalled for possible reduction in effectiveness.
Read More